Business Wire

Flowchem Strengthens Leadership Team, Appointing COO, Technology Team, and Board of Senior Industry Experts

Share

Flowchem (“Flowchem” or the “Company”) and SCFPartners (“SCF”) are pleased to announce several personnel additions. Flowchem is a leading global player in the drag reducing agent (“DRA”) market, providing custom-engineered specialty chemicals to help customers around the world optimize the performance of their infrastructure. These key appointments bolster the already-strong management team in place at the time of the Company’s acquisition in 2024, positioning it for continued growth and industry leadership.

  • Shivali Agarwal has been appointed as Chief Operating Officer (“COO”). Shivali brings decades of industry operating experience in roles across the globe, most recently serving as Group General Manager, Production Systems at SLB (NYSE:SLB). Shivali holds a Master of Business Administration from Harvard Business School and a Master of Science in Biological Sciences and a Bachelor of Science in Chemical Engineering from the Birla Institute of Technology & Science, Pilani, India.

  • Flowchem has bolstered its technology team with several key technical hires, significantly enhancing its product development capabilities. Dr. Lu-Chien Chou is a recognized leader in the field who has led cutting-edge DRA research at Baker Hughes (NASDAQ:BKR) and other DRA providers. John Stephens joins Flowchem after decades of experience in industrial chemical research and development and manufacturing, including at Siege Engineering and PPG Industries (NYSE:PPG). These scientific leaders ensure that Flowchem remains at the forefront of DRA technology while maintaining its industry-leading quality and performance in reducing costs and emissions for customers across multiple product lines.

  • The Company has assembled a best-in-class Board of Directors of senior industry leaders with energy and chemicals experience:

    • Cris Gaut (Chairman) – Chairman and former CEO, Forum Energy Technologies (NYSE:FET); former CFO, Halliburton (NYSE:HAL); former CFO and Co-President, Ensco International

    • Joe Blount – former President and CEO, Colonial Pipeline; former CEO, Century Midstream LLC; former Chair of the Association of Oil Pipe Lines (AOPL)

    • Scott Rogan – CFO, Eagle LNG Partners; former SVP, Targa Resources; former Partner and head of midstream investing, Energy Capital Partners

    • Chris Oversby – former CEO, Optum Energy Solutions, a DRA technology business; former chemicals executive at Baker Hughes, Clariant & Univar

    • Sean Rice – Managing Partner, SCF Partners

    • Dan West – Managing Director, SCF Partners

Flowchem's CEO, Jon Blair, commented, “I am pleased to announce the appointment of Shivali Agarwal to COO. Shivali is a tremendous leader with a proven track record of success, and her operational expertise will enhance our efforts going forward. Our strengthened technology team and strategic board of directors will also be instrumental in improving our DRA solutions and enhancing the value we provide to our customers worldwide.”

Dan West, Managing Director at SCF Partners, stated, “Our team at Flowchem has demonstrated significant success in creating value for both customers and shareholders by making infrastructure operations safer, more efficient, and less emissions-intensive. We are excited to add these key leaders to reinforce and accelerate the company’s growth.”

About Flowchem, Val-Tex, and Sealweld

Flowchem is a leading supplier of Drag Reducing Agents (“DRA”) which optimize pipeline flow and increase throughput capacity. Use of Flowchem DRA enables infrastructure operators across the globe to reduce energy consumed in pumping operations, which in turn reduces both costs and associated greenhouse gas emissions and maximizes overall profitability of infrastructure operations. Flowchem provides flow consultation and turnkey solutions for pipeline applications worldwide. For more information, please visit www.flowchem-dra.com.

Val-Tex, founded in 1962, is one of the industry’s premier providers of high-quality valve maintenance products such as sealants, lubricants, fittings, and injection equipment. Val-Tex’s longstanding commitment to product excellence and customer satisfaction has earned the trust and recommendation of the world’s leading valve manufacturers. To learn more, please visit www.valtex.com.

Sealweld has provided superior valve care products and services since 1969, with a focus on the safe reduction and elimination of pipeline valve leakage. Decades of experience and development of practical solutions have resulted in high-performing valve care products equally suited to either gas or liquid pipelines. For more information, visit www.sealweld.com.

About SCF Partners

Founded in 1989, SCF provides equity capital and strategic growth assistance to build and grow leading energy service, equipment, and technology companies that operate throughout the world. SCF has invested in more than 80 platform companies and made more than 400 additional acquisitions to develop 18 publicly listed energy service and equipment companies over its history. The firm is headquartered in Houston, Texas, and has offices in Calgary, Aberdeen, and Australia. For more information, please visit www.scfpartners.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250210052408/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 02:00:00 CET | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn

Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 00:34:00 CET | Press release

Announcement of Enry’s Island AdVentures: the world’s first video game to learn how to launch and scale startups, focused on democratizing innovation for “Long Tail Users” Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of

500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 21:37:00 CET | Press release

Part of the Digital Morocco 2030 strategy, 500 Global has been selected to support the Startup Venture Building (Startup VB) initiative. 500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to streng

Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 17:00:00 CET | Press release

New capital accelerates Neural Concept’s ability to deliver transformative technologies and enterprise-wide AI impact across advanced industrial workflows.Platform delivers CAD-native, physics-aware AI and deep reasoning for engineering, saving customers $50 million annually, reducing late-stage redesigns by 30-50% and accelerating time to market by up to two years.The company has generated a fourfold increase in enterprise revenue over the past 18 months.More than 50 global companies are actively relying on the platform, including General Motors, General Electric Vernova, Leonardo Aerospace, Eaton, Safran, Renault Group and multiple Formula 1 teams. Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press

Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 16:57:00 CET | Press release

Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special?MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye